In this episode, we delve into a groundbreaking study published in 2026 that challenges long-held beliefs about the genetic causes of vision impairment. The research reveals that many genes linked to inherited eye diseases rarely result in vision loss, prompting a reevaluation of genetic counseling and testing practices.

Next, we explore the new guidelines released by the European Medicines Agency and the U.S. FDA for integrating artificial intelligence into drug development. These principles focus on ethical alignment, human-centric design, and maintaining patient safety while fostering innovation.

We then shift to insights from JPM Week in San Francisco, where biotech leaders discussed the industry's shift from market risk to geopolitical challenges, emphasizing the need to adapt strategies in response to global events.

Meanwhile, Eli Lilly and NVIDIA have announced a $1 billion partnership to establish an AI co-innovation lab, aiming to revolutionize drug development and clinical processes through advanced AI technologies.

Finally, Fresenius Kabi and TQ Therapeutics have teamed up to enhance cell and gene therapy accessibility, integrating cutting-edge cell selection technology to streamline production and accelerate treatment availability for patients.

Stan Berteloot is a French-American journalist, marketing strategist, and AI expert based in Princeton, New Jersey. A University of Maryland journalism graduate, he navigates the intersection of storytelling, technology, and culture.

As Head of Strategy and CTO at Nytro Marketing, he pioneered AI-driven content creation, launching the AI in Marketing podcast. He also hosts Back in America, a podcast exploring American identity through in-depth conversations on race, misinformation, and AI ethics.

Start your VoiceStream free trial today!

📚 Sources:

• https://www.managedhealthcareexecutive.com/view/5-key-takeaways-on-most-favored-nations-pricing-from-mjh-life-sciences-webinar
• https://pharmaphorum.com/news/ema-and-fda-agree-principles-ai-drug-development
• https://medcitynews.com/2026/01/how-does-geopolitics-affect-the-life-sciences-industry-3-executives-weigh-in/
• https://www.mobihealthnews.com/news/jpm-nvidia-and-eli-lilly-announce-co-innovation-ai-lab
• https://www.biospace.com/press-releases/fresenius-kabi-tq-therapeutics-announce-cell-therapy-technology-agreement

In this episode, we explore key developments in the global life sciences and biotech sectors. Telangana is set to unveil its Next-Generation Life Sciences Policy 2026–2030 at the World Economic Forum, aiming to position itself as a top global life sciences hub. The U.S. biotech sector faces challenges from inconsistent funding and regulations, risking its global leadership. Lilly and NVIDIA announce a $1 billion AI-focused co-innovation lab in South San Francisco, while Illumina launches the Billion Cell Atlas to enhance AI-driven drug discovery. Hippocratic AI acquires Grove AI to boost its life sciences capabilities. Changes to the UK's Voluntary Pricing and Access Scheme are underway following a UK-US trade deal. Lastly, Rosanna Zhang from ACROBiosystems discusses the use of organoids in neuroscience research, offering new insights into brain disorders.

Stan Berteloot is a French-American journalist, marketing strategist, and AI expert based in Princeton, New Jersey. A University of Maryland journalism graduate, he navigates the intersection of storytelling, technology, and culture.

As Head of Strategy and CTO at Nytro Marketing, he pioneered AI-driven content creation, launching the AI in Marketing podcast. He also hosts Back in America, a podcast exploring American identity through in-depth conversations on race, misinformation, and AI ethics.

Start your VoiceStream free trial today!

📚 Sources:

• https://www.metroindia.net/news/articlenews/telangana-to-unveil-next-gen-life-sciences-policy-at-davos-34250
• https://www.biospace.com/policy/opinion-trump-must-make-biotech-innovation-a-national-priority
• https://www.drugdiscoverytrends.com/lilly-and-nvidia-unveil-1b-co-innovation-lab-in-sf/
• https://www.genengnews.com/topics/drug-discovery/ai-and-drug-discovery-get-a-boost-from-illuminas-billion-cell-atlas-release
• https://pharmaphorum.com/news/hippocratic-ai-builds-life-sciences-grove-ai-buy
• https://pharmaphorum.com/market-access/changes-uks-vpag-non-submissions-should-be-key-metric-impact
• https://www.news-medical.net/news/20260114/Disease-responsive-nanoparticles-enable-ghrelin-mRNA-therapy-in-osteoarthritis.aspx

In this episode, we explore key developments from the JPMorgan Healthcare Conference, where biotech companies made waves despite the lack of major announcements, highlighting the sector's ongoing growth potential. Chai Discovery's collaboration with Eli Lilly aims to enhance biologics discovery using AI, following a successful Series B funding round. VieCure secured $43 million to expand its AI-powered Halo Intelligence platform, emphasizing democratizing precision medicine. Applied Clinical Trials Online discusses the role of digital technologies in clinical trials, while NVIDIA's partnerships with Eli Lilly and Thermo Fisher aim to integrate AI into drug discovery and laboratory operations. NEJM AI examines cognitive biases in AI systems, stressing the need for fair and accurate applications. The New England Journal of Medicine highlights ethical considerations in medical AI, and JAMA Network Open evaluates AI's reliability in providing nutritional information. Finally, NVIDIA and Eli Lilly's $1 billion investment in an AI co-innovation lab promises to revolutionize drug discovery and manufacturing processes.

Stan Berteloot is a French-American journalist, marketing strategist, and AI expert based in Princeton, New Jersey. A University of Maryland journalism graduate, he navigates the intersection of storytelling, technology, and culture.

As Head of Strategy and CTO at Nytro Marketing, he pioneered AI-driven content creation, launching the AI in Marketing podcast. He also hosts Back in America, a podcast exploring American identity through in-depth conversations on race, misinformation, and AI ethics.

Start your VoiceStream free trial today!

📚 Sources:

• https://www.statnews.com/2026/01/12/noubar-afeyan-letter-investors-jpm-2026/
• https://www.biospace.com/press-releases/chai-discovery-announces-collaboration-with-eli-lilly-and-company-to-accelerate-biologics-discovery
• https://www.mobihealthnews.com/news/viecure-raises-43m-cancer-care-platform
• https://www.appliedclinicaltrialsonline.com/
• https://pharmaphorum.com/news/nvidia-announces-lily-thermo-fisher-partnerships-jpm
• https://ai.nejm.org/doi/abs/10.1056/AIcs2400639
• https://www.nejm.org/doi/full/10.1056/NEJMra2214183
• https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2813295
• https://hitconsultant.net/2026/01/12/nvidia-and-eli-lilly-launch-ai-co-innovation-lab-to-reinvent-drug-discovery/

In this episode, we explore how data, AI, and capital are transforming the life sciences industry as 2026 begins. We start with Accenture and Salesforce's new AI-powered life sciences cloud, designed to streamline operations and improve decision-making. Next, we discuss Alexandra Beneville's appointment at Phreesia, enhancing their life sciences content strategy. We then highlight a company's expanded AI partnership to accelerate clinical development. Eytan Ellenberg delves into the complexities of drug causality, while Haisco Pharmaceutical's AirNexis spinout targets the Western market with a new respiratory treatment. We also cover a study favoring risk-based breast cancer screening over traditional methods. Finally, we examine the $4.9 billion funding surge in biotech as the J.P. Morgan Healthcare Conference approaches.

Stan Berteloot is a French-American journalist, marketing strategist, and AI expert based in Princeton, New Jersey. A University of Maryland journalism graduate, he navigates the intersection of storytelling, technology, and culture.

As Head of Strategy and CTO at Nytro Marketing, he pioneered AI-driven content creation, launching the AI in Marketing podcast. He also hosts Back in America, a podcast exploring American identity through in-depth conversations on race, misinformation, and AI ethics.

Start your VoiceStream free trial today!

📚 Sources:

• https://www.fiercebiotech.com/medtech/accenture-joins-salesforce-build-out-ai-powered-cloud-service-life-sciences-companies
• https://www.mmm-online.com/home/channel/phreesia-appoints-alexandra-beneville-vp-of-life-sciences-content-strategy
• https://www.appliedclinicaltrialsonline.com/view/medidata-biorender-announce-new-ai-partnerships-expanding-capabilities-life-sciences
• https://www.appliedclinicaltrialsonline.com/view/conference-calls-for-unity-in-addressing-artificial-intelligence-regulation-in-life-sciences-research-and-development
• https://www.biocentury.com/article/658026/haisco-steps-onto-global-stage-with-blue-chip-newco-deal
• https://www.managedhealthcareexecutive.com/view/top-3-opportunities-artificial-intelligence-healthcare
• https://endpoints.news/private-and-public-biotechs-go-on-4-8b-funding-spree-ahead-of-jpm/

In this episode, we delve into recent developments in politics, health care, and technology. Former President Donald Trump has called on Republicans to adopt a more flexible approach to abortion restrictions to secure a health care deal, emphasizing the need for compromise to achieve broader legislative goals. Meanwhile, Biobeat Technologies has raised $50 million to introduce its innovative cuffless blood pressure monitor to the U.S. market, despite skepticism from cardiovascular health bodies. Lastly, Insilico Medicine has partnered with Servier in a groundbreaking $888 million collaboration to leverage AI for drug discovery, highlighting the growing role of technology in the pharmaceutical industry. Join us as we explore these stories and their implications for the future.

Stan Berteloot is a French journalist, marketing strategist, and AI expert based in Princeton, New Jersey. A University of Maryland journalism graduate, he navigates the intersection of storytelling, technology, and culture.

As Head of Strategy and CTO at Nytro Marketing, he pioneered AI-driven content creation, launching the AI in Marketing podcast. He also hosts Back in America, a podcast exploring American identity through in-depth conversations on race, misinformation, and AI ethics.

Start your VoiceStream free trial today!

📚 Sources:

• https://www.statnews.com/2026/01/06/fda-pulls-back-oversight-ai-enabled-devices-wearables/?utm_campaign=rss
• https://www.medtechdive.com/news/biobeat-raises-50m-cuffless-blood-pressure/808817/
• https://www.bioworld.com/articles/727787-insilico-inks-888m-drug-discovery-partnership-with-servier

Welcome to today's episode, where we explore the latest in health and technology. OpenAI has launched ChatGPT Health, a new feature designed to integrate personal health information with AI, helping users manage their health more effectively. This innovation reflects a growing trend in healthcare towards using advanced technologies to enhance patient care.

In other news, Surgerii Robotics, a Chinese surgical robot manufacturer, has raised $100 million to expand the global reach of its SHURUI single port endoscopic surgical robot. This advancement highlights the competitive landscape of robotic surgery, with Surgerii competing against major players like Intuitive Surgical.

Shifting to public health, concerns have arisen over potential conflicts of interest as a panel developing new dietary guidelines has financial ties to the beef and dairy industries. This situation raises questions about the integrity and transparency of these influential recommendations.

In the pharmaceutical sector, Eli Lilly is acquiring Ventyx Biosciences for $1.2 billion to bolster its focus on oral immune drugs targeting inflammatory conditions. This acquisition enhances Lilly's portfolio in obesity and metabolic treatments.

Lastly, AI-driven drug discovery company Earendil has secured a $2 billion deal with Sanofi, emphasizing the growing role of AI in the pharmaceutical industry. This partnership aims to accelerate drug discovery, showcasing AI's potential to revolutionize the development of new therapies.

Stay tuned for more insights and updates on the intersection of technology and health.

Stan Berteloot is a French journalist, marketing strategist, and AI expert based in Princeton, New Jersey. A University of Maryland journalism graduate, he navigates the intersection of storytelling, technology, and culture.

As Head of Strategy and CTO at Nytro Marketing, he pioneered AI-driven content creation, launching the AI in Marketing podcast. He also hosts Back in America, a podcast exploring American identity through in-depth conversations on race, misinformation, and AI ethics.

Start your VoiceStream free trial today!

📚 Sources:

• https://medcitynews.com/2026/01/openai-chatgpt-healthcare-privacy-data/
• https://www.medtechdive.com/news/Surgerii-Robotics-raises-100M-fund-global-expansion/809056/
• https://www.statnews.com/2026/01/06/fda-pulls-back-oversight-ai-enabled-devices-wearables/?utm_campaign=rss
• https://www.biopharmadive.com/news/lilly-ventyx-acquire-deal-nlrp3-inflammasome/808988/
• https://www.bioworld.com/articles/727792-ai-drug-discovery-brings-2b-sanofi-deal-to-1-year-old-earendil